GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Purple Biotech
Purple Biotech is an Israeli biotech company developing drugs to treat pancreatic cancer and other tumors. Its stock price is highly volatile and driven by news about the progress of its candidates' clinical trials.
Share prices of companies in the market segment - Cancer cure
Purple Biotech is an Israeli oncology company developing drugs that overcome tumor resistance to treatment. We've categorized it as a "Cancer Treatment" company. The chart below shows how investors value companies working on this complex problem in oncology.
Broad Market Index - GURU.Markets
Purple Biotech is an Israeli oncology company developing drugs to overcome tumor resistance to treatment. It is a component of the GURU.Markets index. The chart below shows the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
PPBT - Daily change in the company's share price Purple Biotech
Purple Biotech Ltd.'s daily price change reflects the extreme volatility inherent in biotech companies. This metric measures its sensitivity to news about the clinical trials of its oncology drugs.
Daily change in the price of a set of shares in a market segment - Cancer cure
Purple Biotech is a clinical-stage biopharmaceutical company developing cancer treatments that target the tumor microenvironment. Oncology is a highly volatile sector. The chart below reflects the average fluctuations in this industry, providing context for evaluating PPBT stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Purple Biotech is an Israeli biotech company developing cancer treatments. Its shares bring the dynamism of this cutting-edge medical field to the US market, adding an international dimension to the overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Purple Biotech
Purple Biotech Ltd.'s year-over-year performance is a story of its oncology drug development. Its 12-month market cap is entirely dependent on clinical trial data. The success of its leading candidates, which are aimed at overcoming chemotherapy resistance, could offer new options for patients with difficult-to-treat cancers.
Annual dynamics of market capitalization of the market segment - Cancer cure
Purple Biotech is an Israeli clinical-stage biotech company. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Purple Biotech is a biotech company whose value is based on the hope of developing a new cancer cure. Its year-over-year performance relative to the market isn't a reflection of business processes, but a speculative bet on clinical trial success. The chart is a series of sharp movements driven by news.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Purple Biotech
Purple Biotech is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its tumor-targeting drugs prompts immediate investor reaction.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Purple Biotech is a clinical-stage oncology company developing drugs that overcome tumor resistance to treatment. The chart below reflects the general sentiment in the cancer drug development sector, where addressing resistance is a key challenge.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Purple Biotech is a clinical-stage oncology company. Its shares represent a binary bet on the success or failure of its scientific developments. Its performance is completely disconnected from market cycles and driven by news about the progress of clinical trials, which implies extreme volatility.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Purple Biotech
Shares of Purple Biotech, an Israeli clinical-stage oncology company, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials of their drug candidates. The chart below is a prime example of how short-term scientific data and investor expectations shape value in innovative medicine.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Purple Biotech is an oncology company developing drugs to combat tumor resistance to treatment. This is one of the key challenges in oncology. The chart clearly shows how clinical trial data, either confirming or refuting its approach, causes sharp fluctuations in its stock price unrelated to the market.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Purple Biotech is a biotech company whose fate depends on scientific data. This chart clearly demonstrates how out of sync its weekly performance can be with the broader market. A single clinical trial announcement can cause massive swings while the S&P 500 remains stagnant.
Market capitalization of the company, segment and market as a whole
PPBT - Market capitalization of the company Purple Biotech
Purple Biotech's valuation on the chart is a bet on its drugs, which target the tumor microenvironment to improve the effectiveness of cancer treatments. This Israeli biotech company's valuation depends on the success of its clinical trials. The dynamics illustrate how investors view this innovative, yet risky, approach to oncology.
PPBT - Share of the company's market capitalization Purple Biotech within the market segment - Cancer cure
Purple Biotech's market share in oncology reflects its focus on overcoming tumor resistance. Its market share is driven by the strength of its drug candidates, which target the tumor microenvironment to make it more susceptible to chemotherapy and immunotherapy.
Market capitalization of the market segment - Cancer cure
This chart shows the total market capitalization of biotech companies developing drugs to combat cancer resistance. Purple Biotech is one such player. The chart's dynamics reflect the hopes associated with finding ways to make chemotherapy and immunotherapy effective again.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the hope for a new way to fight difficult-to-treat cancers. Purple Biotech's market cap reflects investors' faith in its drugs that target the tumor microenvironment. The line shows how the Israeli biotech is fighting for its share of the future of global oncology.
Book value capitalization of the company, segment and market as a whole
PPBT - Book value capitalization of the company Purple Biotech
Purple Biotech's book value represents its scientific capital. The chart below reflects the valuation of its pipeline of developments aimed at overcoming tumor resistance. Growth in the pipeline signals success in clinical trials, which are the primary tangible expression of this biotech company's value.
PPBT - Share of the company's book capitalization Purple Biotech within the market segment - Cancer cure
Purple Biotech's core assets are its laboratories, where drugs are developed to overcome tumor resistance. The chart shows the company's share of this cutting-edge scientific infrastructure, which forms the physical basis for a new approach to oncology.
Market segment balance sheet capitalization - Cancer cure
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Purple Biotech, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Purple Biotech develops drugs that target the tumor microenvironment to make cancer susceptible to therapy. The company's assets are not hospitals, but a research platform and clinical trial data. The chart shows the financial resources devoted to this complex cancer-fighting strategy.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Purple Biotech
Purple Biotech is an Israeli oncology company. Its market capitalization is based on its pipeline of developments aimed at overcoming tumor resistance. This is a bet on its scientific approach to a complex problem in oncology.
Market to book capitalization ratio in a market segment - Cancer cure
Purple Biotech Ltd. is an Israeli biotech company developing cancer treatments. Its value is entirely dependent on the success of its clinical programs. This chart clearly shows how its market valuation is a bet on future drugs and is significantly disconnected from its current assets.
Market to book capitalization ratio for the market as a whole
Purple Biotech is a clinical-stage biotech company developing cancer treatments. Its market valuation, illustrated by this chart, depends almost entirely on the prospects of its scientific developments. The stock's price movement is a barometer of investor sentiment regarding the success of its clinical trials.
Debts of the company, segment and market as a whole
PPBT - Company debts Purple Biotech
Purple Biotech, a clinical-stage biotech focused on cancer treatment, leverages its financial structure to advance its drugs through clinical trials. This chart shows how the company raises capital to fund R&D, aiming to develop new treatments for difficult-to-treat tumors.
Market segment debts - Cancer cure
Purple Biotech is an Israeli clinical-stage biotech developing cancer treatments. This chart shows how its debt load reflects its capital needs to fund expensive clinical trials and how it raises funds to advance its oncology candidates through complex development stages.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Purple Biotech
C3is Inc. is a shipping company that owns dry bulk vessels. Purchasing and servicing vessels is an extremely capital-intensive business, almost always financed with debt. This chart shows the company's high level of financial leverage, making its profits extremely sensitive to volatile shipping rates.
Market segment debt to market segment book capitalization - Cancer cure
Purple Biotech is a clinical-stage biotech developing cancer drugs that overcome tumor resistance. This chart compares its debt load to the overall market capitalization of the oncology sector. It shows how the company funds its research and development.
Debt to book value of all companies in the market
Purple Biotech is a clinical-stage biotech company focused on developing cancer drugs. Funding research before bringing a product to market is a key objective. This chart, reflecting the overall debt situation in the economy, provides insight into the environment in which Purple Biotech is raising capital to advance its oncology programs.
P/E of the company, segment and market as a whole
P/E - Purple Biotech
For Purple Biotech, a clinical-stage oncology company, P/E is not a useful metric. The company has no profit, and its valuation on this chart is arbitrary. The real value is a speculative bet on the success of its clinical trials and the potential of future cancer drugs.
P/E of the market segment - Cancer cure
Purple Biotech is a clinical-stage biotech company developing cancer treatments that target the tumor microenvironment. Their approach is to make tumors more vulnerable to the immune system and chemotherapy. This chart shows the average valuation for the oncology sector, reflecting investor interest in innovative cancer-fighting strategies.
P/E of the market as a whole
Purple Biotech is an Israeli biotech company developing cancer treatments that target the tumor microenvironment. The company's approach is to make tumors more vulnerable to the immune system and chemotherapy. This risk appetite chart helps understand how investors evaluate new oncology strategies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Purple Biotech
Purple Biotech is an Israeli biopharmaceutical company developing cancer treatments that overcome tumor resistance. This chart shows market expectations for the success of its clinical programs. Future profits depend on the results of trials and the commercial potential of its developments.
%20P%2FE%20Purple%20Biotech&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Purple-Biotech&v=1772513493547 "Chart of the company's future (projected) P/E Purple Biotech")
Future (projected) P/E of the market segment - Cancer cure
Purple Biotech is a clinical-stage oncology company developing drugs that target the tumor microenvironment. This chart compares market expectations. It shows how investors view its scientific approach and the potential of its drug candidates compared to other biotech companies fighting cancer.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772513493577 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Purple Biotech is a clinical-stage biopharmaceutical company developing cancer treatments that overcome drug resistance. Its future depends on successful trials. The overall market optimism reflected in this chart is critical for attracting the capital needed to fund innovative oncology research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513493601 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Purple Biotech
Purple Biotech is a clinical-stage biopharmaceutical company focused on cancer treatment. Its financial performance is driven by clinical trial costs. This chart illustrates the significant investments required to develop oncology drugs, where research success is key to future valuation.
Profit of companies in the market segment - Cancer cure
Purple Biotech is a clinical-stage biotech company developing cancer treatments that overcome tumor resistance. This graph, showing overall sector profitability, highlights one of the key challenges in oncology. The success of Purple Biotech's drugs could offer new hope for patients and have a significant impact on the entire industry.
Overall market profit
Purple Biotech is a clinical-stage biotechnology company focused on developing drugs for the treatment of pancreatic cancer and other difficult-to-treat tumors. Its value is determined by progress in clinical trials. It is an example of a company solving complex medical problems whose fate is unaffected by overall economic trends.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Purple Biotech
Purple Biotech is a clinical-stage biopharmaceutical company focused on developing cancer treatments. The future profit projections you see are speculative and depend on the success of its candidates in clinical trials. Analysts are evaluating the potential of its drugs to overcome treatment resistance in tumors.
%20profit%20of%20the%20company%20Purple%20Biotech&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Purple-Biotech&v=1772513493798 "Graph of future (projected) profit of the company Purple Biotech")
Future (predicted) profit of companies in the market segment - Cancer cure
Purple Biotech is a clinical-stage biopharmaceutical company developing cancer treatments that overcome resistance to tumor therapy. This chart shows future revenue projections for the entire oncology sector. It allows one to assess how the company's scientific approach to solving a complex medical problem compares with overall financial expectations in the field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772513493902 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Purple Biotech is a clinical-stage biotech company focused on cancer treatment. Its success depends on trial results. This chart, reflecting overall market sentiment, is critical. Optimistic economic forecasts are driving capital inflows into the high-risk biotech sector, which Purple Biotech needs to fund R&D.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513493929 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Purple Biotech
Purple Biotech is a clinical-stage biotech focused on developing drugs to treat pancreatic cancer and other solid tumors. This metric, which relates market capitalization to minimum revenue, reflects expectations. It demonstrates investor confidence in the company's scientific approach and the potential of its drugs.
P/S market segment - Cancer cure
Purple Biotech is a clinical-stage biotech company specializing in the development of cancer treatments that overcome tumor resistance. The company targets difficult-to-treat cancers. This chart shows how investors value revenue in the oncology sector, demonstrating the level of confidence in Purple Biotech's scientific approach and development pipeline.
P/S of the market as a whole
Purple Biotech is a clinical-stage biopharmaceutical company focused on developing drugs that overcome resistance to cancer treatments. This chart, showing average revenue estimates, demonstrates how biotech companies' valuations depend on the future potential of their research and development pipeline rather than current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Purple Biotech
Purple Biotech is a clinical-stage biotech company focused on cancer treatment. This chart shows the market's assessment of its potential future revenue from drugs in development. It reflects investor confidence in the scientific success of its developments and the commercial potential of its innovative therapies.
%20P%2FS%20Purple%20Biotech&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Purple-Biotech&v=1772513493991 "The graph of the company's future (projected) P/S Purple Biotech")
Future (projected) P/S of the market segment - Cancer cure
Purple Biotech is a clinical-stage biotech company developing drugs to overcome tumor resistance. The chart shows the average estimated future sales in the cancer treatment sector. It helps understand how investors view Purple Biotech's scientific approach and the potential of its candidates to address one of the key challenges in oncology.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772513494009 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Purple Biotech (PPBT) is a clinical-stage biotech company developing cancer treatments. Their future depends solely on the results of clinical trials. This graph of overall economic expectations bears no relation to their valuation, which is determined by the scientific data and potential of their drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513494017 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Purple Biotech
Purple Biotech is a biotech company focused on cancer treatment. Being in the clinical stage, it does not generate revenue from sales of its own drugs. Its revenue comes from milestone payments and royalties from previously licensed assets, as well as from potential future partnerships for its lead drug candidate.
Sales of companies in the market segment - Cancer cure
Purple Biotech is an Israeli clinical-stage oncology company developing drugs that overcome tumor resistance to treatment. It currently has no sales revenue. Its future revenue depends on the success of its candidates targeting pancreatic cancer and other solid tumors.
Overall market sales
Purple Biotech Ltd. is a biotech company developing cancer treatments. Its value is determined by progress in clinical trials. Its operations are not subject to consumer cycles, but the overall economic environment, shown in this chart, influences the investment climate in the biotech sector and its ability to attract capital for expensive R&D.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Purple Biotech
Purple Biotech is a clinical-stage biotech company developing cancer treatments that overcome resistance to therapy. Future revenue depends on the success of its clinical programs. This chart represents analysts' long-term forecast of the commercial potential of its innovative approaches in oncology.
%20sales%20of%20the%20company%20Purple%20Biotech&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Purple-Biotech&v=1772513494085 "Schedule of future (projected) sales of the company Purple Biotech")
Future (projected) sales of companies in the market segment - Cancer cure
Purple Biotech is a clinical-stage biopharmaceutical company developing targeted therapies for the treatment of cancer, particularly pancreatic cancer. This chart shows the outlook for the oncology drug sector. It reflects the urgent need for new treatments for difficult-to-treat cancers, a focus for Purple Biotech.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772513494128 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
The biotech investment climate, illustrated by this chart, is important for Purple Biotech. The company develops cancer treatments. Its ability to fund long-term clinical trials depends on capital inflows into the industry, which increase during periods of overall economic strength.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513494161 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Purple Biotech
Purple Biotech is a clinical-stage biotech company developing drugs to overcome tumor resistance. This chart reflects its investment in research. Future profitability depends on the success of clinical trials and the ability of its drugs to significantly improve cancer treatment outcomes.
Market segment marginality - Cancer cure
Purple Biotech is an Israeli biopharmaceutical company developing cancer treatments that target the tumor microenvironment. Profitability depends on the success of its clinical programs. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing the potential of Purple Biotech's innovative approach to oncology.
Market marginality as a whole
Purple Biotech is a clinical-stage biopharmaceutical company developing cancer treatments. Its success and value depend on the results of clinical trials and partnerships. This chart reflects investor sentiment and their willingness to fund risky but promising oncology developments, which shape the company's future.
Employees in the company, segment and market as a whole
Number of employees in the company Purple Biotech
Purple Biotech is a clinical-stage biotech company focused on cancer treatment. This chart shows the size of its team of scientists and clinical development specialists. A small and focused staff is typical for R&D companies, where changes can reflect progress in clinical trials or a strategic focus on the most promising assets.
Share of the company's employees Purple Biotech within the market segment - Cancer cure
Purple Biotech develops targeted cancer therapies that overcome tumor resistance. Its team of scientists explores complex mechanisms of cancer. This chart shows the company's share of the total number of researchers in its field. This reflects its scientific potential and focus on solving one of the key challenges in cancer treatment.
Number of employees in the market segment - Cancer cure
Purple Biotech is a clinical-stage biopharmaceutical company developing cancer treatments designed to overcome drug resistance. This chart, illustrating employment in the oncology research sector, is important. The growing number of scientists working on resistance demonstrates the high relevance of this area for improving patient outcomes.
Number of employees in the market as a whole
Purple Biotech develops targeted drugs for cancer treatment. Funding in the biotech sector is highly dependent on overall market conditions. This overall employment chart reflects economic health, which attracts investors. During periods of stability and growth, capital is more willing to invest in long-term, risky projects, such as drug development.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Purple Biotech (PPBT)
Purple Biotech is an Israeli biotech company developing drugs for the treatment of cancer (specifically pancreatic cancer). As with any biotech company at the R&D stage, this metric demonstrates a high valuation of "intellectual capital." The market value is a bet on the success of their clinical trials, not on the current productivity of their small staff.
%20of%20the%20company%20Purple%20Biotech%20(PPBT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Purple-Biotech-PPBT&v=1772513494342 "Chart of market capitalization per employee (in thousands of dollars) of the company Purple Biotech (PPBT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Purple Biotech is a biotech company focused on developing cancer drugs. Its market valuation depends on the prospects of its scientific research and clinical trials. This metric clearly demonstrates that in the biotech world, all value can be concentrated in the intellectual property developed by a small but highly valuable team of scientists.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772513494364 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Purple Biotech is a clinical-stage biotech company developing cancer treatments. Its market capitalization is based on the potential of its scientific research. This chart shows the high valuation per employee, typical for biotech, as the market value reflects the expectations of a small but highly qualified scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513494416 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Purple Biotech (PPBT)
Purple Biotech is an Israeli clinical-stage biotech company focused on developing drugs to treat cancer, particularly pancreatic cancer. It's pure R&D. This chart shows the company's capital burn rate: it reflects how much the company invests (negative return) per scientist to conduct expensive clinical trials.
%20Chart%20Purple%20Biotech%20(PPBT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Purple-Biotech-PPBT&v=1772513494464 "Company Profit Per Employee (in thousands of dollars) Chart Purple Biotech (PPBT)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Purple Biotech is a clinical-stage biotechnology company specializing in cancer treatments. While in active research and development, the company incurs significant expenses. This chart helps assess the effectiveness of these expenses. Future growth will depend on successful clinical trials and partnerships.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772513494474 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Purple Biotech (PPBT) is an Israeli biotech company developing cancer treatments, specifically targeting the tumor microenvironment. It is a clinical-stage R&D company. There is no profit. This metric is negative and reflects the "cost" of a single scientist working in the complex field of oncology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513494480 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Purple Biotech (PPBT)
Purple Biotech is a biotech company focused on cancer treatments. This chart shows the minimum revenue from partnerships at the clinical trial stage. Its main value is in demonstrating the future potential that could be realized if their developments are successful.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Purple-Biotech-PPBT&v=1772513494495 "Sales chart per company employee Purple Biotech (PPBT)")
Sales per employee in the market segment - Cancer cure
Purple Biotech is a clinical-stage biotech company focused on cancer treatment, particularly pancreatic cancer. It's a pure R&D operation. This chart clearly shows that the company has no commercial revenue. The productivity of their research team is measured solely by progress in clinical trials.
Sales per employee for the market as a whole
Canada Goose (GOOS) is a luxury outerwear brand known for its premium down jackets. The company combines manufacturing (often in Canada) with direct-to-consumer (DTC) sales through its own flagship stores and online. This chart demonstrates the effectiveness of their vertically integrated model. By managing both production and retail, GOOS strives to maximize revenue from every employee, whether they're a seamstress in the factory or a salesperson.
Short shares by company, segment and market as a whole
Shares shorted by company Purple Biotech (PPBT)
Purple Biotech (PPBT) is an Israeli clinical-stage oncology company. This chart tracks bearish bets. "Short" here is a classic bet on clinical trial failure, the most likely outcome for most companies in this space.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Purple-Biotech-PPBT&v=1772513494550 "Short Shares Chart for the Company Purple Biotech (PPBT)")
Shares shorted by market segment - Cancer cure
Purple Biotech (PPBT) is a biotech company developing cancer treatments that target the tumor microenvironment. The chart below represents a general short position in the oncology biotech sector. It highlights the general investor skepticism regarding the success of risky clinical trials.
Shares shorted by the overall market
Purple Biotech is an Israeli clinical-stage biotech developing cancer drugs. This chart illustrates overall market pessimism. When fear mounts, investors avoid stocks with dual risks: scientific (trial failure) and geopolitical (Israel). CISS falls victim to risk aversion as market panic mounts.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Purple Biotech (PPBT)
This chart for Purple Biotech is an indicator of binary bets in oncology. The company develops drugs that target the tumor microenvironment. "Overbought" levels (above 70) arise from positive Phase 2 data, especially in combination with other drugs. A study failure or toxicity will immediately crash the oscillator (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Purple-Biotech-PPBT&v=1772513494664 "RSI 14 indicator chart for the company's stock Purple Biotech (PPBT)")
RSI 14 Market Segment - Cancer cure
Purple Biotech is an Israeli clinical-stage biotech company focused on developing targeted therapies for cancer, particularly pancreatic cancer. This chart reflects the overall sentiment in the oncology sector and helps assess how overheated this speculative biotech segment is.
RSI 14 for the overall market
Purple Biotech (PPBT) is a biotech company focused on developing cancer treatments. Like many clinical-stage companies, it relies on market funding. This market "temperature" chart shows investor risk appetite. When the market is overheated (euphoric), investors are eager to fund biotechs. During moments of panic (oversold), capital becomes expensive for PPBT.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PPBT (Purple Biotech)
Purple Biotech (PPBT) is an oncology company developing tumor microenvironment-targeted therapies (TAMS) to enhance therapy efficacy. This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of this scientific platform and its early clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PPBT-Purple-Biotech&v=1772513494762 "A chart showing analyst consensus forecasts for the expected stock price. PPBT (Purple Biotech)")
The difference between the consensus estimate and the actual stock price PPBT (Purple Biotech)
Purple Biotech (PPBT) is an Israeli biotech company developing targeted cancer drugs designed to overcome resistance to therapy. This chart measures the gap between the current share price and the consensus target price. It shows how confident experts are in their oncology R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PPBT-Purple-Biotech&v=1772513494780 "A chart showing the difference between the consensus forecast and the actual stock price. PPBT (Purple Biotech)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Purple Biotech is an Israeli biotech company developing targeted drugs (kinase inhibitors) for the treatment of pancreatic cancer and other "cold" tumors. This chart shows the overall analyst expectations for the oncology sector. It reflects whether experts believe R&D success in this complex field is possible.
Analysts' consensus forecast for the overall market share price
Purple Biotech (PPBT) is an Israeli clinical-stage biopharmaceutical company developing drugs that are designed to "hack" tumor defenses, making them vulnerable to the immune system. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough but high-risk R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Purple Biotech
Purple Biotech is an Israeli biotech R&D company focused on tumor hacking. Their R&D pipeline targets the cancer microenvironment, attempting to make tumors visible to the immune system and chemotherapy. This chart is a pure indicator of their R&D confidence. It doesn't reflect revenue, but rather a speculative estimate of their clinical data and their chances of success.
AKIMA Market Segment Index - Cancer cure
Purple Biotech is an Israeli oncology company. They develop drugs that overcome tumor resistance, making chemotherapy and immunotherapy more effective. This chart compares their composite index to the sector, showing how their resistance-fighting strategy compares to others.
The AKIM Index for the overall market
Purple Biotech is a biopharmaceutical company developing cancer treatments that target the tumor microenvironment (NT219). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research story compares to overall economic trends.
